bluebird bio (BLUE) Given a $195.00 Price Target by JPMorgan Chase & Co. Analysts
JPMorgan Chase & Co. set a $195.00 price objective on bluebird bio (NASDAQ:BLUE) in a research note published on Friday morning, TipRanks reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
BLUE has been the topic of several other reports. Zacks Investment Research lowered bluebird bio from a hold rating to a sell rating in a research note on Thursday, January 17th. Canaccord Genuity restated a buy rating and issued a $161.00 target price (down from $250.00) on shares of bluebird bio in a research note on Wednesday, January 23rd. ValuEngine lowered bluebird bio from a buy rating to a hold rating in a research note on Friday, February 22nd. Cantor Fitzgerald restated a neutral rating and issued a $122.00 target price (down from $134.00) on shares of bluebird bio in a research note on Friday, February 22nd. Finally, BMO Capital Markets boosted their target price on bluebird bio to $194.00 and gave the company an outperform rating in a research note on Friday, February 22nd. Eleven equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $168.29.
BLUE stock traded down $6.86 during midday trading on Friday, hitting $121.48. The company’s stock had a trading volume of 476,700 shares, compared to its average volume of 527,112. The company has a current ratio of 9.31, a quick ratio of 9.31 and a debt-to-equity ratio of 0.09. bluebird bio has a 1 year low of $87.49 and a 1 year high of $199.70. The stock has a market cap of $7.07 billion, a P/E ratio of -11.37 and a beta of 2.50.
In related news, insider David Davidson sold 6,360 shares of the business’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $160.06, for a total transaction of $1,017,981.60. Following the sale, the insider now directly owns 37,976 shares in the company, valued at approximately $6,078,438.56. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jeffrey T. Walsh sold 1,500 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $139.80, for a total value of $209,700.00. Following the sale, the insider now owns 42,421 shares in the company, valued at $5,930,455.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,530 shares of company stock worth $4,710,113. 3.00% of the stock is currently owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the stock. Icon Wealth Partners LLC bought a new stake in shares of bluebird bio during the 1st quarter valued at $31,000. Exane Derivatives bought a new stake in shares of bluebird bio during the 4th quarter valued at $34,000. Macquarie Group Ltd. bought a new stake in shares of bluebird bio during the 1st quarter valued at $72,000. Quadrant Capital Group LLC raised its stake in shares of bluebird bio by 211.5% during the 1st quarter. Quadrant Capital Group LLC now owns 486 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 330 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of bluebird bio by 36.6% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,104 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 296 shares during the period.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Further Reading: What are Bollinger Bands?
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.